Insights

Loading spinner
Gathering insights about Surface Oncology Inc.

Surface Oncology Inc. Tech Stack

Surface Oncology Inc. uses 8 technology products and services including SiteCatalyst, SAS, Mimecast, and more. Explore Surface Oncology Inc.'s tech stack below.

  • SiteCatalyst
    Analytics
  • SAS
    Business Intelligence
  • Mimecast
    Email Security
  • Adobe Fonts
    Font Scripts
  • Modernizr
    Javascript Libraries
  • HSTS
    Security
  • VMware
    Virtualisation Software
  • Nginx
    Web Servers

Media & News

Surface Oncology Inc.'s Email Address Formats

Surface Oncology Inc. uses at least 1 format(s):
Surface Oncology Inc. Email FormatsExamplePercentage
FLast@surfaceoncology.comJDoe@surfaceoncology.com
49%
Last@surfaceoncology.comDoe@surfaceoncology.com
2%
FLast@surfaceoncology.comJDoe@surfaceoncology.com
49%

Frequently Asked Questions

Where is Surface Oncology Inc.'s headquarters located?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s main headquarters is located at 50 Hampshire Street 8th Floor Cambridge, MA 02139 US. The company has employees across 5 continents, including North AmericaEuropeAsia.

What is Surface Oncology Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Surface Oncology Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Surface Oncology Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s official website is surfaceoncology.com and has social profiles on LinkedIn.

How much revenue does Surface Oncology Inc. generate?

Minus sign iconPlus sign icon
As of January 2025, Surface Oncology Inc.'s annual revenue reached $15M.

What is Surface Oncology Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Surface Oncology Inc. have currently?

Minus sign iconPlus sign icon
As of January 2025, Surface Oncology Inc. has approximately 51 employees across 5 continents, including North AmericaEuropeAsia. Key team members include Chief Medical Officer: A. M. O.Chief Scientific Officer: V. P.Executive Assistant To The Ceo: B. H.. Explore Surface Oncology Inc.'s employee directory with LeadIQ.

What industry does Surface Oncology Inc. belong to?

Minus sign iconPlus sign icon
Surface Oncology Inc. operates in the Biotechnology Research industry.

What technology does Surface Oncology Inc. use?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s tech stack includes SiteCatalystSASMimecastAdobe FontsModernizrHSTSVMwareNginx.

What is Surface Oncology Inc.'s email format?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s email format typically follows the pattern of . Find more Surface Oncology Inc. email formats with LeadIQ.

How much funding has Surface Oncology Inc. raised to date?

Minus sign iconPlus sign icon
As of January 2025, Surface Oncology Inc. has raised $29M in funding. The last funding round occurred on May 20, 2020 for $29M.

When was Surface Oncology Inc. founded?

Minus sign iconPlus sign icon
Surface Oncology Inc. was founded in 2014.
Surface Oncology Inc.

Surface Oncology Inc.

Biotechnology ResearchMassachusetts, United States51-200 Employees

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors"​, have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. 
We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.
Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work.  
From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.

Section iconCompany Overview

Headquarters
50 Hampshire Street 8th Floor Cambridge, MA 02139 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $29M

    Surface Oncology Inc. has raised a total of $29M of funding over 4 rounds. Their latest funding round was raised on May 20, 2020 in the amount of $29M.

  • $10M$50M

    Surface Oncology Inc.'s revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $29M

    Surface Oncology Inc. has raised a total of $29M of funding over 4 rounds. Their latest funding round was raised on May 20, 2020 in the amount of $29M.

  • $10M$50M

    Surface Oncology Inc.'s revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.